1. Home
  2. CGEM vs WSR Comparison

CGEM vs WSR Comparison

Compare CGEM & WSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$15.80

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Whitestone REIT

WSR

Whitestone REIT

HOLD

Current Price

$19.00

Market Cap

973.9M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
WSR
Founded
2016
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
973.9M
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
CGEM
WSR
Price
$15.80
$19.00
Analyst Decision
Strong Buy
Hold
Analyst Count
8
5
Target Price
$30.13
$19.00
AVG Volume (30 Days)
766.7K
370.7K
Earning Date
05-11-2026
05-01-2026
Dividend Yield
N/A
3.01%
EPS Growth
N/A
31.94
EPS
N/A
0.08
Revenue
N/A
$160,859,000.00
Revenue This Year
N/A
$2.77
Revenue Next Year
$5.20
$4.21
P/E Ratio
N/A
$237.38
Revenue Growth
N/A
4.26
52 Week Low
$5.68
$11.43
52 Week High
$16.74
$19.01

Technical Indicators

Market Signals
Indicator
CGEM
WSR
Relative Strength Index (RSI) 60.10 82.39
Support Level $11.92 $18.90
Resistance Level $16.10 $19.00
Average True Range (ATR) 0.98 0.03
MACD 0.22 -0.10
Stochastic Oscillator 80.89 85.00

Price Performance

Historical Comparison
CGEM
WSR

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About WSR Whitestone REIT

Whitestone REIT is a real estate investment trust (REIT) that owns and operates commercial properties in culturally diverse metropolitan markets. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business-friendly locations in and around Austin, Scottsdale, Dallas, Houston, Phoenix, Arizona, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.

Share on Social Networks: